Healthcare Purchasing News
  • Magazine
  • Continuing Education
  • Webinars
  • Whitepapers
  • Videos
  • Events
  • Hall of Fame
  • Advertise
  • Source Guide
  • Subscribe
  • Sourcing & Logistics
  • Sterile Processing
  • Surgical & Critical Care
  • Patient Satisfaction
  • Infection Prevention
  • EVS & Facility Services
  • Healthcare IT
  • Regulatory
  • Topics
    Sourcing & LogisticsSterile ProcessingSurgical & Critical CarePatient SatisfactionInfection PreventionEVS & Facility ServicesHealthcare ITRegulatory
    Resources
    HPN Source GuideContinuing EducationWebinarsWhitepapersVideosEventsHall of FameAdvertiseAd Specs
    User Tools
    SubscribeContact UsAbout UseNewsletterMagazinesPrivacy PolicyTerms & Conditions
    https://www.facebook.com/hpnonline
    https://www.linkedin.com/company/healthcare-purchasing-news/
    https://twitter.com/HPN_Online
    1. Infection Prevention
    2. Screening & Surveillance

    Measuring COVID-19 viral RNA to predict which patients will die

    Dec. 1, 2021
    Courtesy of CDC
    22910

    The amount of a SARS-CoV-2 genetic material—viral RNA—in the blood is a reliable indicator in detecting which patients will die of the disease, a team led by Université de Montréal medical professor Dr. Daniel Kaufmann has found.

    The finding is published in Science Advances. Kaufmann and his team did the work at the CRCHUM, the research arm of UdeM’s teaching hospital, the Centre hospitalier de l’Université de Montréal.

    “In our study, we were able to determine which biomarkers are predictors of mortality in the 60 days following the onset of symptoms,” said Kaufmann, the study’s co-lead author alongside CRCHUM research colleagues Nicolas Chomont and Andrés Finzi.

    “Thanks to our data, we have successfully developed and validated a statistical model based on one blood biomarker,” viral RNA, Kaufmann said.

    Despite advances in the management of COVID-19, doctors have found it hard to identify patients most at risk of dying of the disease and so be able to offer them new treatments. Several biomarkers have been identified in other studies, but juggling the profusion of parameters is not possible in a clinical setting and hinders doctors’ ability to make quick medical decisions.

    Using blood samples collected from 279 patients during their hospitalization for COVID-19, ranging in degrees of severity from moderate to critical, Kaufmann’s team measured amounts of inflammatory proteins, looking for any that stood out.

    At the same time, Chomont’s team measured the amounts of viral RNA and Finzi’s the levels of antibodies targeting the virus. Samples were collected 11 days after the onset of symptoms and patients were monitored for a minimum of 60 days after that.

    The goal: to test the hypothesis that immunological indicators were associated with increased mortality.

    “Among all of the biomarkers we evaluated, we showed that the amount of viral RNA in the blood was directly associated with mortality and provided the best predictive response, once our model was adjusted for the age and sex of the patient,” said Elsa Brunet-Ratnasingham, a doctoral student in Kaufmann’s lab and co-first author of the study.

    To confirm its effectiveness, Kaufmann and Brunet-Ratnasingham tested the model on two independent cohorts of infected patients from Montreal’s Jewish General Hospital (recruited during the first wave of the pandemic) and the CHUM (recruited during the second and third waves).

    It made no difference which hospital the patients were treated at, nor which period of the pandemic they fell into: in all cases, the predictive model worked. Now Kaufmann and his colleagues want to put it to practical use.

    University of Montreal report

    More on COVID

    Latest in Screening & Surveillance

    By Gorodenkoff on AdobeStock
    Adobe Stock 416534355
    Screening & Surveillance

    Agreement hopes to spur enhanced, global access to COVID testing technologies

    June 16, 2022
    By ustas on AdobeStock
    Adobe Stock 229043399
    Screening & Surveillance

    New research shows severe COVID is in the genes

    June 15, 2022
    By Stockwerk-Fotodesign on Adobe Stock
    Adobe Stock 331271554
    Screening & Surveillance

    New study makes Delta the deadliest

    May 24, 2022
    Courtesy of the CDC
    Courtesy of the CDC
    Regulatory

    CDC update on children with Acute Hepatitis of Unknown Cause

    May 19, 2022
    Courtesy of UK Health Security Agency (UKHSA)
    Courtesy of UK Health Security Agency (UKHSA)
    Screening & Surveillance

    Four more cases of monkeypox identified by the UK Health Security Agency

    May 18, 2022
    Healthcare Purchasing News
    https://www.facebook.com/hpnonline
    https://www.linkedin.com/company/healthcare-purchasing-news/
    https://twitter.com/HPN_Online
    • About Us
    • Contact Us
    • Advertise
    • Do Not Sell or Share
    • Privacy Policy
    • Terms & Conditions
    © 2023 Endeavor Business Media, LLC. All rights reserved.
    Endeavor Business Media Logo